Business
Mesoblast (ASX:MSB) share price soars 14% on clinical trial results
The Mesoblast Limited (ASX: MSB) share price rocketed on news that the company’s drug, rexlemestrocel-L, is showing promising signs.
The Mesoblast share price closed today’s trade 14.29% higher at $2.56 per share. Notably, today is the highest its shares have been since the failure of remestemcel-L in treating COVID-19 patients was announced in late December.
Why is the Mesoblast share price soaring?
Mesoblast announced that a single dose of its drug rexlemestrocel-L provides a reduction in heart attacks, strokes and cardiac death in patients with chronic heart failure.
The results come from its landmark, randomised controlled phase 3 trial with 537 patients. Of the patients, who all had chronic heart failure, some received…
-
General24 hours agoGymnastics club in Berwick shuts down following child safety complaint
-
General18 hours agoAshes engulfed by fresh DRS controversy as TV umpire gives Jamie Smith out despite RTS ‘murmur’
-
Noosa News22 hours agoMeticulously crafted home in heart of Noosa Heads
-
General21 hours ago‘Mother’s Day’ solar storm squeezed Earth’s plasmasphere to one-fifth its size